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Abstract
Objective To examine the relation between the normal range
of serum aminotransferase concentration and mortality from
liver disease.
Design Prospective cohort study.
Setting Korea Medical Insurance Corporation study with eight
years’ follow up.
Participants 94 533 men and 47 522 women aged 35-59 years.
Main outcome measure Mortality from liver diseases according
to death certificate.
Results There was a positive association between the
aminotransferase concentration, even within normal range
(35-40 IU/l), and mortality from liver disease. Compared with
the concentration < 20 IU/l, the adjusted relative risks for an
aspartate aminotransferase concentration of 20-29 IU/l and
30-39 IU/l were 2.5 (95% confidence interval 2.0 to 3.0) and 8.0
(6.6 to 9.8) in men and 3.3 (1.7 to 6.4) and 18.2 (8.1 to 40.4) in
women, respectively, The corresponding risks for alanine
aminotransferase were 2.9 (2.4 to 3.5) and 9.5 (7.9 to 11.5) in
men and 3.8 (1.9 to 7.7) and 6.6 (1.5 to 25.6) in women,
respectively. According to receiver operating characteristic
curves the best cut-off values for the prediction of liver disease
in men were 31 IU/l for aspartate aminotransferase and 30
IU/l for alanine aminotransferase.
Conclusion People with slightly increased aminotransferase
activity, but still within the normal range, should be closely
observed and further investigated for liver diseases.
Introduction
Serum aminotransferase assays are the most common
laboratory tests for the detection of liver diseases. Because the
enzyme concentration in a population forms a continuous distri-
bution, the cut-off concentration that discriminates between
healthy and diseased livers is not clearly defined. The upper nor-
mal limit of serum aminotransferase is set on average at 40 IU/l,
ranging from 30-50 IU/l.1 2 The normal range is calculated from
a supposedly healthy reference population. However, reference
populations probably include people with mild to moderate
chronic liver diseases.3 4 The use of the current normal range
may lead to an underestimated prevalence of liver disease. The
normal range may also be determined from prospective studies
on the association between enzyme concentration and long term
mortality. However, there is little information on the association
between serum aminotransferase concentration and mortality
from liver diseases, especially for relatively low concentrations of
aminotransferase. The significance of serum aminotransferase
concentration in relation to mortality needs reviewing, and the
need for a full investigation in the general population still
remains.
Methods
Study population
We selected participants from the cohort used in the Korea
Medical Insurance Corporation study. The corporation provides
health insurance to government and private school employees
and their dependents. In 1990, the corporation insured
1 213 594 workers and 3 389 767 dependents, about 11% of the
total Korean population. The corporation required all insured
workers to take a biennial health examination. The study cohort
consisted of 115 200 men and 67 932 women, aged 35-59 years
in 1990, who underwent health examinations in 1990 and 1992.
We had data on serum aminotransferase assay and smoking and
alcohol intake for 102 741men and 51 180 women.We excluded
162 men and 21 women who died before 1993 and 8046 men
and 3637 women who had any known diseases at baseline and
enrolled 94 533 men and 47 522 women for the analysis.
Data collection
We obtained baseline information from the health examinations
in 1990 and 1992 and the self reported questionnaire in 1992. At
each examination participants’ weight, height, and blood
pressure were measured. Fasting blood samples were analysed
for plasma glucose concentrations and serum cholesterol and
aminotransferase concentrations. The average of two measure-
ments was used for the analysis. From the 1992 questionnaire, we
collected information on smoking and alcohol consumption, any
previously known diseases, and family history of chronic
diseases.
The outcome variable was mortality from death certificates.
The follow up period was eight years (1993-2000). We carried
out a computerised search of the death certificate data from the
National Statistical Office. We used three categories of liver
disease classified by ICD-9 or ICD-10 (international classification
of diseases, ninth and 10th revisions) for the analysis: liver
cancer, liver disease other than cancer, and all liver diseases. In
the survival analyses, of the deaths from liver diseases as
recorded on the death certificates, we used data only for those
patients who had previously been admitted to hospital with liver
disease. Information on hospital admissions was obtained from
the health insurance claim data.
Statistical analysis
We classified participants according to body mass index
(quarters); serum total cholesterol concentration (quarters);
plasma glucose concentration ( < 5.6 mmol/l, 5.6-6.9 mmol/l,
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and ≥ 7.0 mmol/l); blood pressure (normal, prehypertension,
hypertension5); smoking (current smokers, former smokers, non-
smokers); and alcohol consumption (non-drinker and four
groups of drinkers based on the average daily alcohol intake:
< 50 g/day, 50-99 g/day, 100-199 g/day, and ≥ 200 g/day). We
calculated daily intake of alcohol by multiplying the frequency
and the amount of alcohol consumed a day for those who drank
once a week or more on average. The family history of liver dis-
ease was used as a dichotomous variable: no/unknown and yes.
Cox proportional hazard regression analysis was used to control
for age and the above variables. We have represented multivari-
ate adjusted relative risks of mortality with 95% confidence inter-
vals, which were estimated by treating the relative risks as floating
absolute risks to show the appropriate variability for each
concentration of serum aminotransferase.6
We plotted the receiver operating characteristic curve of the
serum aminotransferase concentration for the detection of
future mortality from liver disease. Usually the best cut-off value
in a receiver operating characteristic curve is the value that max-
imises the sum of the sensitivity and specificity, which is the point
nearest to the top left hand corner.
Results
At the baseline examination, aminotransferase concentration
was positively associated with blood pressure, fasting plasma glu-
cose concentration, and total serum cholesterol concentration.
Cigarette smoking, alcohol consumption, and the family history
of liver disease were also associated with raised aminotransferase
concentrations (table 1).
During the eight years’ follow up 3392 men and 394 women
died. The mortality per 100 000 person years was 456 for men
and 104 for women. The number of deaths from liver disease was
690, and 524 were confirmed by the previous admission history.
Mortality from liver disease was positively associated with
baseline age, serum aminotransferase concentration, and blood
pressure in both sexes. Family history of liver diseases, high fast-
ing plasma glucose concentration, low total serum cholesterol
concentration, and heavy drinking were also correlated with
mortality from liver disease in men (table 2).
There was a continuous and positive association between
aminotransferase concentration and mortality in men. Mortality
from diseases of the digestive system, in which liver diseases
accounted for 89%, was most strongly correlated to the
aminotransferase concentration. Mortality from cancer and
cardiovascular disease was also correlated with aminotransferase
concentration. Because of the relatively small number of deaths
from liver diseases in women, we could not adequately assess the
cause specific mortality (table 3).
The association between the aminotransferase concentration
and mortality from liver disease was significant, even within the
current normal limits. Compared with the lowest concentration
( < 20 IU/l), the risks for mortality from liver disease for aspartate
and alanine aminotransferase concentrations at 20-29 IU/l (only
in men) and 30-39 IU/l were significantly increased. Both liver
cancer and liver disease other than cancer were associated with
the serum aminotransferase concentration in men (table 4), but
liver disease in women could not be classified (table 5).
We estimated that the best cut-off values for identifying men
who are risk of death from liver disease were 31 IU/l for aspar-
tate aminotransferase and 30 IU/l for alanine aminotransferase.
The areas under the receiver operating characteristic curve were
0.83 and 0.78, respectively (fig 1). We could not establish the cut-
off value in women, but we would expect it to be lower than in
men.
Discussion
The cross sectional association between serum aminotransferase
concentration and liver disease is well known. However, little is
Table 1 Baseline characteristics by serum aminotransferase concentration* in 94 533 men and 47 522 women
Baseline characteristics
Men Women
All levels
(n=94 533)
By concentration All levels
(n=47 522)
By concentration
Normal (n=84 287) Raised (n=10 246) P value Normal (n=46 575) Raised (n=947) P value
Mean (SD)
Age (years) 44.8 (6.7) 44.8 (6.7) 44.4 (6.5) <0.001 42.0 (6.0) 42.0 (6.0) 44.5 (6.8) <0.001
Body mass index, kg/m2 23.4 (2.4) 23.3 (2.3) 23.4 (2.6) <0.001 22.2 (2.4) 22.2 (2.4) 23.7 (3.0) <0.001
Systolic blood pressure (mm Hg) 125.2 (13.9) 124.8 (13.7) 128.8 (14.6) <0.001 115.8 (12.2) 115.7 (12.1) 120.9 (14.9) <0.001
Diastolic blood pressure (mm Hg) 82.0 (9.4) 81.7 (9.4) 84.3 (9.7) <0.001 75.3 (8.8) 75.2 (8.8) 78.8 (10.2) <0.001
Fasting plasma glucose (mmol/l) 5.1 (1.0) 5.1 (1.0) 5.4 (1.2) <0.001 4.8 (0.6) 4.8 (0.6) 5.1 (1.0) <0.001
Total serum cholesterol (mmol/l) 5.0 (0.9) 5.0 (0.8) 5.2 (1.0) <0.001 4.9 (0.8) 4.9 (0.8) 5.2 (1.0) <0.001
Serum AST (IU/l) 25.7 (13.3) 23.0 (5.7) 48.0 (28.3) <0.001 20.3 (7.2) 19.8 (5.0) 46.4 (26.2) <0.001
Serum ALT (IU/l) 25.2 (15.9) 21.5 (6.7) 55.5 (30.9) <0.001 17.4 (8.9) 16.7 (5.5) 54.1 (33.1) <0.001
Number (%)
Smoking status:
Non-smoker 20 147 (21.3) 18 160 (21.5) 1 987 (19.4) <0.001 47 131 (99.2) 46 193 (99.2) 938 (99.1) 0.797
Ex-smoker 19 477 (20.6) 17 498 (20.8) 1 979 (19.3) 391 (0.8)† 382 (0.8)† 9 (0.9)†
Current smoker 54 909 (58.1) 48 629 (57.7) 6 280 (61.3)
Average alcohol consumption:
Non-drinker 27 643 (29.2) 24 961 (29.6) 2 682 (26.2) <0.001 44 933 (94.5) 44 046 (94.5) 887 (93.7) 0.253
<50 g/day 57 901 (61.3) 51 832 (61.5) 6 069 (59.2) 2 559 (5.5)‡ 2 529 (5.5)‡ 60 (6.3)‡
≥50 g/day 8 989 (9.5) 7 494 (8.9) 1 495 (14.6)
Family history of liver disease:
Yes 3 436 (3.6) 2 994 (3.6) 442 (4.3) <0.001 482 (1.0) 464 (1.0) 18 (1.9) 0.010
No/unknown 91 097 (96.4) 81 293 (96.4) 9 804 (95.7) 47 040 (99.0) 46 111 (99.0) 929 (98.1)
AST=aspartate aminotransferase, ALT=alanine aminotransferase.
*Aminotransferase concentration defined as normal when AST<40 IU/l and ALT <40 IU/l and raised when AST ≥40 IU/l and/or ALT ≥40 IU/l.
†Smoking in women defined as non-smoker or any smoking.
‡Alcohol consumption in women defined as non-drinker or any drinking.
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known about the enzyme concentrations in relation to prospec-
tive mortality. We found a strong relation between aminotrans-
ferase concentrations and long term mortality. We also found
that a slightly increased but still normal aminotransferase
concentration is related to increased risk of death from liver dis-
ease.
Mortality from liver disease and normal serum
aminotransferase concentration
There could be several explanations for the increased risk of
mortality in men with slightly increased but still normal enzyme
concentrations. Firstly, mortality may be due to unrecognised
liver diseases. Several studies have reported the presence of liver
diseases in men (chronic active or persistent hepatitis and
cirrhosis) with the normal or slightly increased aminotransferase
concentration.7–9 Chronic hepatitis C virus infection in people
with a persistently normal aminotransferase concentration
(HCV with PNAL) also has been reported.10–13 Secondly, the rela-
tion may be due to other risk factors for liver disease.
Aminotransferase activity is associated with factors such as obes-
ity, alcohol consumption, serum cholesterol concentration, and
plasma glucose concentration.14–16 Even after we adjusted for
such risk factors, we observed an independent association
between the aminotransferase concentration and mortality from
liver disease. Thirdly, advanced chronic liver diseases with
relatively low enzyme activity may contribute to the association.
This is unlikely, however, as we excluded men with known liver
diseases and used the average of two enzyme measurements at
two year intervals. Our data suggest that the association is prob-
ably due to unrecognised liver diseases. Individuals with slightly
increased aminotransferase concentrations need close observa-
tion and further investigation for liver diseases.
Though we consistently observed an association between
serum aminotransferase concentration and mortality from liver
disease in men, we could not do so in women because mortality
from liver diseases in woman is low. In Korea the prevalance of
hepatitis B infection in men is twice as high as in women. We
speculated that men with hepatitis B virus infection are at
higher risk of liver deterioration. In fact, mortality from liver
disease in Korean men is four times higher than in women.17 18
Further studies are required to determine the normal range
and the impact of serum aminotransferase concentration in
women.
Application of results
Recently, Prati et al proposed that the upper normal limit of
serum alanine aminotransferase should be revised to 30 IU/l.4
The outcome of the application of the updated normal upper
limit is increased sensitivity (76.3%) with acceptable specificity
(88.5%) in identifying active C viral hepatitis during six month
follow up.4 Our data agree with this report. If we applied the new
cut-off value, the sensitivity of the tests in identifying men who at
risk of death from liver disease would be increased from 52.3% to
69.7% for aspartate aminotransferase and from 44.5% to 65.4%
for alanine aminotransferase.
However, updating the current normal range remains
controversial. Lowering the upper normal limits will increase
the number of asymptomatic patients with abnormal amino-
transferase concentration, which may increase the healthcare
costs. The lower upper limit will limit blood supplies.19 While
sensitivity and specificity are constant properties of a test,
predictive value is highly dependent on the prevalence of
disease in the population. Although the aminotransferase tests
have reasonable sensitivity and specificity, their positive predic-
tive value is low: 3.66% with the current normal range and
1.93% with the normal range proposed in this study. Because we
used mortality as the end point, the values may be much lower
than the real value. The low predictive value may be still a prob-
lem, especially in a population with a relatively low prevalence
of liver disease. A more practical solution may be to divide the
current normal upper limit into the optimal concentration
( < 30 IU/l) and the borderline concentration (30-39 IU/l). Indi-
viduals with a borderline aminotransferase concentration may
be candidates for further studies4 on secondary prevention of
liver diseases.
Although the specificity is low, the serum aminotransferase
assay is an inexpensive and useful test in screening for liver dis-
ease, especially in areas where liver diseases are prevalent. Low-
ering the upper limit in such areas will facilitate early detection
of chronic liver diseases and thus possibly prevent mortality. In
most Western regions, the aminotransferase assay may be less
useful as a mass screening tool, though reviewing the normal
range of serum aminotransferase concentration may still be use-
ful in special settings such as screening of blood donors, medical
check up of haemodialysis patients, and preoperative evaluation.
People who repeatedly show increased aminotransferase
concentrations according to the lowered normal upper limit
should be further investigated by serum biochemistry, viral
marker tests, and ultrasonography. The cost effectiveness of this
Table 2 Association between baseline characteristics and risk of mortality
from liver diseases. Figures are relative risks (95% confidence intervals)
Baseline characteristics Men Women
Age (per one year increase) 1.05 (1.04 to 1.06) 1.14 (1.07 to 1.21)
Raised AST (≥40 IU/l) 18.17 (15.24 to 21.66) 22.53 (8.36 to 60.67)
Raised ALT (≥40 IU/l) 8.93 (7.49 to 10.64) 27.32 (11.24 to 66.40)
Family history of liver disease 2.62 (1.93 to 3.56) —
Body mass index* (kg/m2):
<21.75 (<20.51) 1.00 1.00
21.75-23.38 (20.51-22.06) 0.87 (0.68 to 1.10) 0.76 (0.17 to 3.37)
23.39-25.0 (22.07-23.72) 0.82 (0.64 to 1.05) 0.25 (0.03 to 2.27)
≥25.01 (≥23.75) 0.83 (0.65 to 1.06) 3.83 (1.27 to 11.55)
Blood pressure:
Normal 1.00 1.00
Prehypertension 1.11 (0.89 to 1.39) 2.99 (1.21 to 7.41)
Hypertension 1.91 (1.46 to 2.49) 3.63 (0.75 to 17.45)
Fasting plasma glucose (mmol/l):
<6.1 1.00 1.00
6.1-6.9 2.10 (1.77 to 2.57) 0.68 (0.09 to 5.04)
≥7.0 3.18 (2.29 to 4.42) —
Total serum cholesterol* (mmol/l):
<4.4 (<4.3) 1.00 1.00
4.4-4.8 (4.3-4.7) 0.63 (0.50 to 0.79) 1.32 (0.46 to 3.80)
4.9-5.4 (4.8-5.3) 0.49 (0.38 to 0.62) 0.97 (0.31 to 3.01)
≥5.5 (≥5.4) 0.48 (0.37 to 0.61) 0.50 (0.13 to 2.01)
Smoking:
Non-smoker 1.00 1.00
Past smoker 1.07 (0.81 to 1.42) —
Current smoker 1.20 (0.95 to 1.51) —
Ever smoked — 5.53 (0.75 to 41.04)
Alcohol consumption (g/day):
Non-drinker 1.00 1.00
<50 0.78 (0.64 to 0.94) —
50-99 0.96 (0.68 to 1.35) —
100-199 1.09 (0.58 to 2.06) —
≥200 3.33 (1.64 to 6.76) —
Drinker — 1.66 (0.39 to 7.08)
AST=aspartate aminotransferase, ALT=alanine aminotransferase.
*Figures in parentheses are ranges for women.
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approach still needs to be evaluated prospectively in various
settings.
Strength and weakness
This study has several strong points. Firstly, it was performed
with a large population (142 055 people) and had a long follow
up period (eight years). Previous studies have had a cross
sectional design or short follow up period, and they failed to
investigate the association between serum aminotransferase
concentration and long term mortality.4 20–22 Eight years may not
be long enough to follow the entire clinical course of liver
disease because of its wide variation. However, we had a
considerable number of outcome events because of the large
study population and the high prevalence of liver diseases in
Korea. Secondly, the results can be generalised to the broader
Korean population and, perhaps, to other populations as well.
While previous studies investigated special populations, such as
blood donors and haemodialysis patients, our study cohort was
recruited from the nationwide general population.4 20–22 Thirdly,
the use of repeated measurements of variables decreased the
possibility of measurement error or misclassification bias.
Finally, to increase the validity of the causes of death, we verified
Table 3 Relative risk of mortality by all causes by the serum aminotransferase concentration at baseline (expressed as floating absolute risks)
Total No of
Participants
All causes Cancers Cardiovascular diseases Diseases of digestive system
No of
deaths RR* (95% CI)
No of
deaths RR* (95% CI)
No of
deaths RR* (95% CI)
No of
deaths RR* (95% CI)
Men
AST (IU/l):
<20 26 416 619 1.0 (0.9 to 1.1) 292 1.0 (0.9 to 1.1) 118 1.0 (0.8 to 1.2) 18 1.0 (0.6 to 1.6)
20-29 48 185 1 494 1.3 (1.2 to 1.4) 665 1.2 (1.1 to 1.3) 318 1.4 (1.2 to 1.5) 58 1.8 (1.4 to 2.4)
30-39 13 964 590 1.7 (1.6 to 1.9) 262 1.7 (1.5 to 1.9) 107 1.4 (1.2 to 1.7) 51 5.6 (4.2 to 7.3)
40-49 3 127 219 2.7 (2.4 to 3.1) 98 2.8 (2.3 to 3.4) 33 1.8 (1.3 to 2.5) 36 16.9 (12.2 to 23.5)
50-99 2 397 358 5.4 (4.9 to 6.0) 158 5.5 (4.7 to 6.4) 39 2.6 (1.9 to 3.6) 79 42.7 (34.1 to 53.6)
≥100 444 112 8.6 (7.2 to 10.4) 39 6.7 (4.9 to 9.2) 9 3.3 (1.7 to 6.4) 46 120.4 (89.2 to 162.5)
ALT (IU/l):
<20 37 425 1 061 1.0 (0.9 to 1.1) 494 1.0 (0.9 to 1.1) 197 1.0 (0.9 to 1.2) 34 1.0 (0.7 to 1.4)
20-39 36 589 1 197 1.2 (1.1 to 1.3) 535 1.2 (1.1 to 1.3) 263 1.3 (1.2 to 1.5) 61 2.1 (1.6 to 2.7)
30-39 11 975 516 1.7 (1.5 to 1.8) 215 1.6 (1.4 to 1.8) 85 1.3 (1.0 to 1.6) 60 6.9 (5.4 to 9.0)
40-49 4 068 225 2.2 (1.9 to 2.5) 93 2.1 (1.7 to 2.6) 38 1.7 (1.2 to 2.3) 40 13.5 (9.9 to 18.5)
50-99 3 887 310 3.0 (2.7 to 3.4) 133 3.1 (2.6 to 3.6) 32 1.4 (1.0 to 2.0) 72 23.4 (18.5 to 29.6)
≥100 589 83 5.2 (4.2 to 6.4) 44 6.2 (4.6 to 8.3) 9 2.9 (1.5 to 5.6) 21 41.0 (26.7 to 63.1)
Women
AST (IU/l):
<20 25 362 185 1.0 (0.9 to 1.2) 104 1.0 (0.8 to 1.2) 28 1.0 (0.7 to 1.6) 1 1.0 (0.1 to 7.1)
20-29 19 463 174 1.0 (0.9 to 1.2) 113 1.2 (1.0 to 1.5) 22 0.7 (0.5 to 1.1) 2 2.3 (0.3 to 16.7)
30-39 2 114 24 1.2 (0.7 to 1.6) 12 1.0 (0.6 to 1.8) 2 0.4 (0.1 to 1.6) 2 18.5 (2.8 to 139.6)
40-49 336 3 0.8 (0.3 to 2.5) 3 1.5 (0.5 to 4.6) 0 — 0 —
≥50 247 8 2.9 (1.4 to 5.8) 3 2.1 (0.7 to 6.5) 0 — 3 —
ALT (IU/l):
<20 35 187 257 1.0 (0.9 to 1.2) 154 1.0 (0.8 to 1.2) 32 1.0 (0.6 to 1.6) 2 1.0 (0.3 to 4.0)
20-29 10 201 103 1.2 (1.0 to 1.4) 62 1.2 (0.9 to 1.5) 17 1.3 (0.8 to 2.2) 2 2.7 (0.7 to 11.8)
30-39 1 380 19 1.4 (0.9 to 2.2) 11 1.4 (0.8 to 2.6) 3 1.3 (0.4 to 4.1) 0 —
40-49 365 10 3.0 (1.6 to 5.6) 6 3.1 (1.4 to 6.8) 0 — 2 75.0 (19.7 to 314.7)
≥50 389 5 1.2 (0.5 to 3.0) 2 0.9 (0.2 to 3.5) 0 — 2 80.8 (19.7 to 314.4)
AST=aspartate aminotransferase, ALT=alanine aminotransferase.
*Adjusted for age, body mass index, smoking status, alcohol consumption, plasma glucose, serum total cholesterol, blood pressure, and family history of liver disease.
Table 4 Relative risk of mortality from liver diseases in men by serum aminotransferase concentration at baseline (expressed as floating absolute risks)
Total No of
participants
Liver diseases Liver cancer Non-cancer liver diseases
No of deaths RR* (95% CI) No of deaths RR* (95% CI) No of deaths RR* (95% CI)
AST (IU/l):
<20 26 416 25 1.0 (0.7 to 1.5) 14 1.0 (0.6 to 1.7) 11 1.0 (0.6 to 1.8)
20-29 48 185 108 2.5 (2.0 to 3.0) 76 3.1 (2.5 to 3.9) 32 1.7 (1.2 to 2.3)
30-39 13 964 98 8.0 (6.6 to 9.8) 64 9.4 (7.4 to 12.0) 34 6.2 (4.4 to 8.7)
40-49 3 127 70 25.7 (20.3 to 32.5) 44 29.5 (21.9 to 39.8) 26 20.8 (14.1 to 30.6)
50-99 2 397 149 65.7 (55.8 to 77.4) 92 74.6 (60.7 to 91.8) 57 55.0 (42.2 to 71.7)
≥100 444 51 111.3 (84.0 to 147.4) 17 65.4 (30.4 to 105.9) 34 167.2 (117.8 to 237.2)
ALT (IU/l):
<20 37 425 45 1.0 (0.7 to 1.4) 27 1.0 (0.7 to 1.5) 18 1.0 (0.6 to 1.6)
20-29 36 589 113 2.9 (2.4 to 3.5) 82 3.4 (2.8 to 4.3) 31 2.0 (1.4 to 2.8)
30-39 11 975 110 9.5 (7.9 to 11.5) 64 9.3 (7.3 to 11.9) 46 9.9 (7.4 to 13.2)
40-49 4 068 74 19.2 (15.3 to 24.2) 44 19.3 (14.3 to 26.0) 30 19.1 (13.3 to 27.4)
50-99 3 887 117 30.0 (25.0 to 36.1) 69 30.2 (23.8 to 38.4) 48 29.6 (22.2 to 39.5)
≥100 589 42 59.0 (43.4 to 80.1) 21 46.8 (30.4 to 72.1) 21 78.5 (51.0 to 120.9)
AST=aspartate aminotransferase, ALT=alanine aminotransferase.
*Adjusted for age, body mass index, smoking status, alcohol consumption, plasma glucose, serum total cholesterol, blood pressure, and family history of liver disease.
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morality from liver diseases by reviewing data on hospital
admissions.
Potential limitations of this study include the brief
information on pre-existing diseases, lack of other laboratory
tests for liver diseases, and non-standardised aminotransferase
assays. Firstly, as the objective medical history of the study
population was not available, we used the information provided
by participants. We excluded people who indicated that they
had any previously known diseases. We also assessed the
confounding effects of unknown pre-existing disease by
comparing the results by different follow up periods. However,
the difference in the follow up period did not affect the associ-
ation (table 6). Secondly, we did not study viral marker or
perform liver function tests other than aminotransferase assays
in the baseline examination. Individuals with the family history
of liver disease are at high risk of the chronic hepatitis B virus
infection because the infection is common in Korea, 5-10% in
men and 1-5% in women, and transmitted horizontally in high
frequency.17 23 We assessed the effects of the family history of
liver disease using a stratified analysis. The results showed that
family history of liver diseases did not alter the outcome of the
study (fig 2). Thirdly, 419 hospitals over the country conducted
the health examination and the serum aminotransferase assay
was not standardised. All hospitals, however, followed the inter-
nal and external quality control procedures as stipulated by the
Korean Society of Quality Control in Clinical Pathology. The
variation index score was acceptable: 107 for aspartate
aminotransferase and 109 for alanine aminotransferase.24 The
misclassification bias, if any, is likely to be non-differential
reduction of the relative risk. Hence, the results are unlikely to
be distorted by measurement error.
Conclusion
Our findings indicate that serum aminotransferase concen-
tration is associated with mortality from liver disease, even
within the current normal range. To prevent early death
related to liver diseases, individuals with slightly increased
aminotransferase concentration should be observed closely
and tested further for the presence of diseases. The adjustment
of the normal limit of serum aminotransferase may be
necessary, especially in populations in which liver diseases are
common.
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Table 5 Relative risk of mortality from liver diseases in women by serum
aminotransferase concentration at baseline (expressed as floating absolute
risks)
Total No of
participants
Liver diseases
No of deaths RR* (95% CI)
AST (IU/l):
<20 25 362 3 1.0 (0.3 to 3.2)
20-29 19 463 9 3.3 (1.7 to 6.4)
30-39 2 114 6 18.2 (8.1 to 40.4)
40-49 336 3 46.1 (14.9 to 147.4)
≥50 247 2 46.2 (11.0 to 180.4)
ALT (IU/l):
<20 35 187 6 1.0 (0.4 to 2.3)
20-29 10 201 8 3.8 (1.9 to 7.7)
30-39 1 380 2 6.6 (1.5 to 25.6)
40-49 365 5 68.3 (27.4 to 162.0)
≥50 389 2 21.5 (5.3 to 85.6)
AST=aspartate aminotransferase, ALT=alanine aminotransferase.
*Adjusted for age, body mass index, smoking status, alcohol consumption, plasma glucose,
serum total cholesterol, blood pressure, and family history of liver disease.
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Fig 1 Receiver operating characteristic (ROC) curves of serum aminotransferase concentration for identification of people at risk of death from liver diseases
Table 6 Relation between serum aminotransferase concentration and
mortality from liver disease in men by follow up period. Figures are relative
risks* (95% confidence intervals)
Year 1993-6 Year 1997-2000
Serum aspartate aminotransferase level (IU/l):
<20 1.0 (0.6 to 1.7) 1.0 (0.6 to 1.8)
20-29 1.8 (1.3 to 2.4) 3.3 (2.6 to 4.3)
30-39 6.4 (4.8 to 8.7) 10.0 (7.6 to 13.0)
40-49 17.2 (11.8 to 25.2) 36.3 (26.9 to 49.1)
50-99 46.8 (36.5 to 59.9) 89.4 (71.9 to 111.2)
≥100 61.6 (38.9 to 97.6) 178.8 (115.5 to 254.9)
Serum alanine aminotransferase level (IU/l):
<20 1.0 (0.6 to 1.6) 1.0 (0.7 to 1.5)
20-29 3.1 (2.4 to 4.2) 2.7 (2.1 to 3.4)
30-39 12.5 (9.7 to 16.3) 7.6 (5.8 to 9.9)
40-49 21.4 (15.2 to 30.2) 17.8 (13.1 to 24.2)
50-99 27.5 (20.4 to 36.9) 31.6 (25.0 to 40.0)
≥100 30.0 (16.0 to 55.9) 82.8 (58.4 to 117.5)
*Adjusted for age, body mass index, smoking status, alcohol consumption, plasma glucose,
serum total cholesterol, blood pressure, and family history of liver disease.
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What is already known on this topic
The serum aminotransferase test with upper normal limit
of 40 IU/l can identify liver damage
Little is known about the association between the normal
range of the serum aminotransferase concentration and
mortality
What this study adds
Serum aminotransferase concentration, even under 40 IU/l,
is positively associated with mortality from liver disease
The sensitivity of the serum aminotransferase test with the
current normal range is low in identifying individuals at risk
of death from liver disease
Lowering the normal range of the serum aminotransferase
concentration is advisable in populations in which liver
diseases are common
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Fig 2 Association between serum aminotransferase concentration and mortality
from liver disease in men by presence of family history of liver disease
(expressed as floating absolute risks)
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